Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Phase II trial of lazertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive (M plus ), metastatic non-small cell lung cancer (NSCLC) with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15)
- Authors
- Hong, Min Hee; Choi, Yoon Ji; Ahn, Hee Kyung; Keam, Bhumsuk; Kim, Yu Jung; Kim, Ju Won; Kim, Hye Ryun; Kang, Jin-Hyoung
- Issue Date
- Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- Go to Link
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.